All Updates

All Updates

icon
Filter
Funding
Santa Ana Bio raises USD 168 million in Series A and B funding to advance anti-inflammatory programs to clinical trials
Precision Medicine
Jun 13, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 13, 2024

Santa Ana Bio raises USD 168 million in Series A and B funding to advance anti-inflammatory programs to clinical trials

Funding

  • Santa Ana Bio has raised USD 168 million after Series A and B financing rounds. The Series A round, which raised USD 43 million, was led by Versant Ventures and saw participation from TPG's Life Science Innovations Fund and GV. The Series B round, which raised USD 125 million, was led by GV with new investors Andreessen Horowitz (a16z) Bio + Health, RTW, and Access Biotechnology.

  • The company plans to use these funds to advance two programs into clinical trials for inflammatory conditions by next year. It uses a proteomic, transcriptomic, and genomic approach that attempts to focus on disease-causing cells while sparing healthy ones, addressing ongoing shortcomings in trials such as patient heterogeneity, durability of response, and safety.

  • Santa Ana Bio is a biotechnology company focused on developing precision immunology solutions for autoimmune and inflammatory diseases by leveraging advanced multi-omics platforms and antibody engineering. The company’s pipeline includes several development-stage programs for multiple disease areas, including SAB01 for urticaria, food allergy, and asthma, and SAB 03 for rheumatoid arthritis, inflammatory bowel disease, asthma, and ankylosing spondylitis (axial spondyloarthritis).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.